• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

20.10 +0.81 (+4.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,405,859
Open 19.29
Bid (Size) 19.00 (400)
Ask (Size) 20.50 (2,100)
Prev. Close 19.29
Today's Range 19.09 - 20.15
52wk Range 12.99 - 25.59
Shares Outstanding 69,484,053
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Syndax Announces Participation in September Investor Conferences
Today 7:00 EDT
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax (SNDX) Q2 2026 Earnings Call Transcript ↗
August 11, 2026
Revenue surged 92% year-over-year to $72.8 million, driven by Revuforj and Niktimvo. 
Via The Motley Fool
Topics Earnings

Performance

YTD
-5.6%
-5.6%
1 Month
+4.5%
+4.5%
3 Month
+9.3%
+9.3%
6 Month
-6.1%
-6.1%
1 Year
+24.7%
+24.7%

More News

Read More
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 05, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Q2 Earnings Call Highlights ↗
August 04, 2026
Via MarketBeat
Topics Earnings
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Drop as Q2 Revenue and EPS Miss Estimates ↗
August 04, 2026
Via Chartmill
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Stock Slides After Q1 Revenue Misses Street Forecasts Despite 224% Growth ↗
April 30, 2026
Via Chartmill
News headline image
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
August 04, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
July 28, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push ↗
July 14, 2026
Via MarketBeat
News headline image
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
July 14, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 01, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗
March 26, 2026
Via Chartmill
News headline image
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
June 11, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
June 11, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 04, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
June 04, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
June 02, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
June 01, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
May 21, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation in Upcoming Investor Conferences
May 20, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
May 12, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 06, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
April 24, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?
Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market
What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 20.10
When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 09/01/26 04:00 PM ET
What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.40B
How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
Syndax Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap